Phase I and II clinical trials of an oral RAGE inhibitor azeliragon, with insinuations in attenuating inflammation and hence side effects of chemotherapy, including anthracycline-induced cardiotoxicity and chemotherapy-induced cognitive debility in patients with breast cancer, and cerebral edema post-surgery in patients with glioblastoma, via inhibition of RAGE pathway have been conducted most recently in Georgetown University, Washington and City of Hope Medical Center, California, respectively [125, 127]. This evidence concerns the gene AGER and breast cancer.